Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma
Abstract
Checkpoint inhibitor (CPI) therapy has emerged as treatment option in selected patients with resectable head and neck squamous cell carcinoma. Recent phase III data have led to approval of perioperative pembrolizumab for patients with PD-L1-positive (CPS ≥ 1). With emerging data on adjuvant checkpoint inhibitor therapy the selection of the optimal treatment strategy is becoming increasingly complex. Several clinical phase II/III trials have evaluated neoadjuvant immunotherapy in resectable head and neck cancer, demonstrating both clinical and immunological benefits. This review summarizes current data on neoadjuvant and perioperative checkpoint inhibitors in resectable head and neck cancer and addresses main immunological advantages. In addition, potential strategies to optimize treatment efficacy and to overcome resistance mechanisms of CPI therapy are discussed. Further trials are needed to define optimal treatment protocols, determinate the best timing of surgery, and identify reliable biomarkers for patient selection, to guide evidence-based therapeutic decision-making in routine clinical practice.
Read the paper
Related studies
- Safety and efficacy of COVID‐19 vaccines: A systematic review and meta‐analysis of controlled and randomized clinical trials
- Accuracy Comparison between Robot-Assisted Dental Implant Placement and Static/Dynamic Computer-Assisted Implant Surgery: A Systematic Review and Meta-Analysis of In Vitro Studies
- Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis
- Cleaning efficacy of EDDY versus ultrasonically-activated irrigation in root canals: a systematic review and meta-analysis
- Bonding Efficacy of Universal Resin Adhesives to Zirconia Substrates: Systematic Review and Meta-Analysis
- In vitro antimicrobial activity of extracts and essential oils of Cinnamomum, Salvia, and Mentha spp. against foodborne pathogens: A meta-analysis study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.